Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Figure 1

Clinical trial success rates. Clinical trial success rates in hepatitis C are compared against the industry expectations for each phase of clinical trial testing. The transition probability indicates the likelihood that a drug will successfully complete the phase of testing and will transition to the next phase or FDA approval for those in phase III. Cumulative pass rates represent the product of the probabilities of all three clinical trial phases. The sample size, , indicates the number of drug compounds that have successfully completed that phase.